Scopus Biopharma Inc. Financials
This page shows Scopus Biopharma Inc. (SCPS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Scopus Biopharma Inc. passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Scopus Biopharma Inc. generates $0.70 in operating cash flow (-$8.1M OCF vs -$11.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Scopus Biopharma Inc. generated $0 in revenue in fiscal year 2022.
Scopus Biopharma Inc.'s EBITDA was -$11.7M in fiscal year 2022, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 57.6% from the prior year.
Scopus Biopharma Inc. generated -$8.1M in free cash flow in fiscal year 2022, representing cash available after capex. This represents an increase of 28.9% from the prior year.
Scopus Biopharma Inc. reported -$11.6M in net income in fiscal year 2022. This represents an increase of 56.9% from the prior year.
Scopus Biopharma Inc. earned $-0.55 per diluted share (EPS) in fiscal year 2022. This represents an increase of 64.7% from the prior year.
Scopus Biopharma Inc. held $125K in cash against $0 in long-term debt as of fiscal year 2022.
Scopus Biopharma Inc. had 21M shares outstanding in fiscal year 2022. This represents an increase of 0.0% from the prior year.
Scopus Biopharma Inc. invested $2.7M in research and development in fiscal year 2022. This represents a decrease of 82.1% from the prior year.
Scopus Biopharma Inc. invested $2K in capex in fiscal year 2022, funding long-term assets and infrastructure. This represents a decrease of 22.4% from the prior year.
SCPS Income Statement
| Metric | Q2'23 | Q1'23 | Q2'22 | Q3'22 | Q1'22 | Q4'21 | Q3'21 | Q2'21 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $2.0M+23.9% | $1.6M+115.7% | $746K-18.7% | $917K+148.5% | $369K+171.8% | $136K+75.2% | $78K-99.4% | $13.6M |
| SG&A Expenses | $936K-12.6% | $1.1M-1.8% | $1.1M+11.1% | $981K-77.1% | $4.3M-32.8% | $6.4M+138.0% | $2.7M+55.3% | $1.7M |
| Operating Income | N/A | N/A | -$1.8M+3.3% | -$1.9M+59.3% | -$4.7M+28.5% | -$6.5M-136.2% | -$2.8M+81.9% | -$15.3M |
| Interest Expense | N/A | N/A | $0 | $0 | $0 | $0-100.0% | $111K-66.7% | $332K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$2.6M-6.8% | -$2.4M-41.5% | -$1.7M+8.8% | -$1.9M+59.3% | -$4.7M+28.5% | -$6.5M-365.5% | -$1.4M+91.0% | -$15.6M |
| EPS (Diluted) | $-0.07+12.5% | $-0.080.0% | $-0.08+11.1% | $-0.09+59.1% | $-0.22+24.1% | $-0.29-262.5% | $-0.08+91.8% | $-0.97 |
SCPS Balance Sheet
| Metric | Q2'23 | Q1'23 | Q2'22 | Q3'22 | Q1'22 | Q4'21 | Q3'21 | Q2'21 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $498K-69.0% | $1.6M+308.7% | $392K-5.6% | $416K-91.0% | $4.6M-43.7% | $8.2M+103.1% | $4.0M-40.8% | $6.8M |
| Current Assets | $496K-69.0% | $1.6M+310.6% | $390K-5.6% | $413K-91.0% | $4.6M-43.7% | $8.2M+103.2% | $4.0M-40.8% | $6.8M |
| Cash & Equivalents | $362K-74.2% | $1.4M+1025.0% | $125K-59.9% | $311K-92.2% | $4.0M-50.0% | $7.9M+118.7% | $3.6M-42.0% | $6.3M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $9.9M+16.4% | $8.6M+22.9% | $7.0M+17.5% | $5.9M+15.2% | $5.1M+23.2% | $4.2M+86.4% | $2.2M-74.6% | $8.8M |
| Current Liabilities | $11.0M+18.1% | $9.3M+24.9% | $7.5M | N/A | N/A | $4.2M+86.4% | $2.2M-74.6% | $8.8M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$9.5M-36.1% | -$6.9M-5.8% | -$6.6M-19.3% | -$5.5M-937.6% | -$530K-113.2% | $4.0M+123.9% | $1.8M+190.5% | -$2.0M |
| Retained Earnings | -$58.1M-4.7% | -$55.5M-4.6% | -$53.1M-3.4% | -$51.3M-11.3% | -$46.1M-11.2% | -$41.5M-18.7% | -$34.9M-4.2% | -$33.5M |
SCPS Cash Flow Statement
| Metric | Q2'23 | Q1'23 | Q2'22 | Q3'22 | Q1'22 | Q4'21 | Q3'21 | Q2'21 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.0M-32.8% | -$760K-80.1% | -$422K+50.5% | -$852K+78.6% | -$4.0M+4.1% | -$4.1M-64.8% | -$2.5M-28.2% | -$2.0M |
| Capital Expenditures | N/A | N/A | $0 | $0-100.0% | $2K | $0-100.0% | $2K | $0 |
| Free Cash Flow | N/A | N/A | -$422K+50.5% | -$852K+78.6% | -$4.0M+4.1% | -$4.1M-64.7% | -$2.5M-28.3% | -$2.0M |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | -$45K-102.2% | $2.0M+734.7% | $242K | $0 | $0-100.0% | $8.5M+8214.6% | -$105K-446.4% | -$19K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
SCPS Financial Ratios
| Metric | Q2'23 | Q1'23 | Q2'22 | Q3'22 | Q1'22 | Q4'21 | Q3'21 | Q2'21 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -525.9%-373.1pp | -152.8%+288.4pp | -441.2%+15.5pp | -456.8%-355.6pp | -101.2%-21.5pp | -79.6%-44.9pp | -34.7%+194.8pp | -229.6% |
| Current Ratio | 0.05-0.1 | 0.17+0.1 | 0.05 | N/A | N/A | 1.96+0.2 | 1.80+1.0 | 0.77 |
| Debt-to-Equity | -1.05+0.2 | -1.23-0.2 | -1.06+0.0 | -1.08+8.6 | -9.69-10.7 | 1.04-0.2 | 1.25+5.7 | -4.43 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$6.6M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.05), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Scopus Biopharma Inc.'s annual revenue?
Scopus Biopharma Inc. (SCPS) reported $0 in total revenue for fiscal year 2022. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Scopus Biopharma Inc. profitable?
No, Scopus Biopharma Inc. (SCPS) reported a net income of -$11.6M in fiscal year 2022.
What is Scopus Biopharma Inc.'s earnings per share (EPS)?
Scopus Biopharma Inc. (SCPS) reported diluted earnings per share of $-0.55 for fiscal year 2022. This represents a 64.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Scopus Biopharma Inc.'s EBITDA?
Scopus Biopharma Inc. (SCPS) had EBITDA of -$11.7M in fiscal year 2022, measuring earnings before interest, taxes, depreciation, and amortization.
What is Scopus Biopharma Inc.'s free cash flow?
Scopus Biopharma Inc. (SCPS) generated -$8.1M in free cash flow during fiscal year 2022. This represents a 28.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Scopus Biopharma Inc.'s operating cash flow?
Scopus Biopharma Inc. (SCPS) generated -$8.1M in operating cash flow during fiscal year 2022, representing cash generated from core business activities.
What are Scopus Biopharma Inc.'s total assets?
Scopus Biopharma Inc. (SCPS) had $392K in total assets as of fiscal year 2022, including both current and long-term assets.
What are Scopus Biopharma Inc.'s capital expenditures?
Scopus Biopharma Inc. (SCPS) invested $2K in capital expenditures during fiscal year 2022, funding long-term assets and infrastructure.
How much does Scopus Biopharma Inc. spend on research and development?
Scopus Biopharma Inc. (SCPS) invested $2.7M in research and development during fiscal year 2022.
How many shares does Scopus Biopharma Inc. have outstanding?
Scopus Biopharma Inc. (SCPS) had 21M shares outstanding as of fiscal year 2022.
What is Scopus Biopharma Inc.'s current ratio?
Scopus Biopharma Inc. (SCPS) had a current ratio of 0.05 as of fiscal year 2022, which is below 1.0, which may suggest potential liquidity concerns.
What is Scopus Biopharma Inc.'s debt-to-equity ratio?
Scopus Biopharma Inc. (SCPS) had a debt-to-equity ratio of -1.06 as of fiscal year 2022, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Scopus Biopharma Inc.'s return on assets (ROA)?
Scopus Biopharma Inc. (SCPS) had a return on assets of -2959.7% for fiscal year 2022, measuring how efficiently the company uses its assets to generate profit.
What is Scopus Biopharma Inc.'s cash runway?
Based on fiscal year 2022 data, Scopus Biopharma Inc. (SCPS) had $125K in cash against an annual operating cash burn of $8.1M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Scopus Biopharma Inc.'s debt-to-equity ratio negative or unusual?
Scopus Biopharma Inc. (SCPS) has negative shareholder equity of -$6.6M as of fiscal year 2022, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Scopus Biopharma Inc.'s Piotroski F-Score?
Scopus Biopharma Inc. (SCPS) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Scopus Biopharma Inc.'s earnings high quality?
Scopus Biopharma Inc. (SCPS) has an earnings quality ratio of 0.70x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.